Dual Antiplatelet Therapy After Stent Implantation

• Autores: Stephen J. Greene, Lora Alkhawam, Muthiah Vaduganathan
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 311, Nº. 14, 2014, págs. 1446-1446
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • The Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) trial1 contributes to the body of evidence supporting an improved safety profile of second-generation drug-eluting stents compared with first-generation models.2 However, although it is tempting to simplify the question of the duration of dual antiplatelet therapy to one of stent model or generation, data must be carefully viewed in the context of multiple patient and clinical trial characteristics other than the type of stent involved.